International Journal of Science and Research (IJSR)
ISSN: 2319-7064
SJIF (2022): 7.942

Dostarlimab in Cancer: Cure or a Buzz?

Rythm Walia

Abstract: ***Dostarlimab, a monoclonal body is now being used as an immunotherapy drug for treating cancer. A monoclonal body is a type of protein that is particularly produced in a laboratory to serve as substitute antibodies that can reinstate, amplify, alter, or imitate the immune systems strike on cells that are unwanted and harmful, such as cancer cells. Cancer being the second leading cause of deaths in the US; according to the recent reports, is now a major threat to the society especially to the urban groups. Among all the worst cases of cancer, endometrial cancer has been the most predictable type gynecologic malignancy in the advanced world. Endometrial Cancer (EC) has been assorted as microsatellite stable or microsatellite instability-high; upto 30% of all ECs are categorized as dMMR and MSI-H. Since the spotting of a molecular subclassification system for EC, experiments in immune checkpoint inhibitor therapies are trying to focus on evident subgroups prognostic for response, specifically microsatellite instability-hypermutated or DNA mismatch repair-deficient EC. This review outlines existing data on Dostarlimab and explains if it is really a cure or a buzz.***

Keywords: Dostarlimab, monoclonal bodies, endometrial cancer, dMMR, MSI-H

1. Introduction

Cancer is graded as a dominant cause of mortality worldwide in the 21st century and is accounted for about 10 million deaths in 2020. In 2020, diagnosis and treatment of cancer was negatively impossible to predict the number of cancer cases around the world. In US, the new cancer cases and deaths to be evaluated will be 1.9 million and 609,360 respectively but they do not evince the results of the COVID pandemic as they are emanated from the frequency and mortality data recorded through 2018 and 2019 discretely. The supposition of Cancer being the result of piled up genetic mutations in the DNA of a cell was first revealed by Nordling and later by Knudson. Carcinogens, including radiation, chemicals, and viruses, was found to be inducing cancer in both experimental animals and humans. Carcinomas are malignant tumors occurring from epithelial tissues and cover 90% human cancers. When cancer multiplies in the inner lining of the uterus, it is known as endometrial cancer (EC) which can further be graded on the basis of its spreading speed. Grade 1 doesn't form, grow or spread rapidly (~80%) whereas Grade 2 can be harmful since it extends out of the uterus (~25%). There can be poorly differentiated unwanted growths near the gynecological area which are termed as Grade 3 endometrial tumors (~5%). EC can be compartmented as microsatellite stable/ DNA mismatch repair proficient (MSS/MMRp) and microsatellite instability-high/ DNA mismatch repair deficient (MSI-H/dMMR).

Dostarlimab is termed as a monoclonal antibody which is used as a drug in treating endometrial/ colorectal cancer by inhibiting PD-1 pathway, especially for adults with advanced or recurrent mismatch repair deficient (dMMR) endometrial cancer. It is considered to be a part of immunotherapy which is sold under the brand name Jemperli and has been approved by the FDA but some believe it to be the master start of the cure of cancer. It is proved that it can medicate cancers like endometrial cancer and colorectal cancer but is lacking in the remedy of other cancer types and the proof came from a single trial performed on 18 patients, from which only 12 patients completed the trial. Can it be considered a success or just a hastiness for the cure?

2. Study Design

Dostarlimab was invented in alliance between TESARO and AnaptysBio, Inc. as a IgG4 isotype which causes hinderance in the programmed cell death protein (PD-1) pathway to interact with PD-L1 and PD-L2. PD-1 was first contrived by T. Honjo& colleagues in 1992 in Kyoto University as an apoptosis related gene. PD-1 pathway is expressed by all T-cells; PD-1 receptors being present on T-cells, acts as a spontaneous brake during activation by inhibiting immune responses agents acting on the PD-1 pathway (nivolumab and pembrolizumab). Antitumor immunity can be highly induced by targeting this pathway but after monotherapy with PD-1 blocking mash-up, only a small part of coalition of patients developed lasting clinical responses while most of the patients gave no particular responses. Dostarlimab is now going through various trials on different cancer patients to check its potential but the first trial to get concurred in was publicized by using the GARNET study. It was shown that Dostarlimab was exemplifying a flair in treating a variant of women who were suffering from advanced or recurrent endometrial cancer. It has been an indication of explorative evidence of clinical pursuit and supportable welfare profile in the infirm with endometrial cancers. Deficiency of mismatch repair (dMMR) protein or high microsatellite instability is linked to 20-30% of those endometrial cancers. According to a trial conducted at Memorial Sloan Kettering Cancer Center (MSK) on a group of people suffering from rectal cancer, 100% of those who completed it were cured. Even after a period of time there was no recurrence of the disease. This convinced the Food and Drug Administration (FDA) enough to approve the drug, Dostarlimab, which further was tried to cure other types of cancer but it didn't go as planned rather it showed some adverse reactions. Patients from different places all over the world showed different after affects like in the US, fatigue/ asthenia, nausea, diarrhea, anemia, and constipation were the common side effects while in the EU vomiting, joint pain, itching, rash, fever, and hypothyroidism were common. Less than 2% of the patients went through some serious adverse reactions like sepsis, acute kidney injury, urinary tract infection, abdominal pain, and pyrexia. Immune mediated adverse reactions can also occur inclusive of pneumonitis, colitis, hepatitis, nephritis, and endocrinopathies. An early recognition and regulation of

such adverse reactions is vitally important to clinch the safe use of PD-1 blocking antibodies and for any grade 3 or grade 4 immune-related adverse reaction, treatment with Jemperli should be permanently stopped. In a total of 515 patients who took the medicine, 7 suffered from pneumonitis (grade 2 & 3), 1 from grade 3 hepatitis, 8 from grade 2 & 3 colitis, 37 from grade 2 endocrinopathies which included 7 patients with adrenal insufficiency (grade 2 & 3), 10 patients with hyperthyroidism (grade 2 & 3), and 2 patients with grade 2 thyroiditis, 3 suffered from grade 2 nephritis, 17 from grade 3 rashes for 41 days and 21 patients went through grade 3 arthralgia for median time of 87 days. It's not these reactions weren't resolved; most of the patients recovered after taking some other medical treatment but wouldn't it make the patients physically and mentally weak? Even a minor cold, flu or reaction can cause a lot of damage to the body making it infirm. As we have studied before, Dostarlimab is particularly for adults but can it make sure that even after the immunotherapy, the side effects would not kill the patients? Some may resolve the effects but those who can't handle them can suffer a lot or may even die. Age can become a major point in this as most of the people above the age group of 50-60 years can't handle such medicaments or after effects.

Another matter which should be discussed is the price of Dostarlimab which is extreme for most of the patients around the globe. Dostarlimab is measured out over a span of 30 minutes via intravenous (IV) infusion. 500 mg of Dostarlimab-gxly dose is suggested to the patients for every 3 weeks (doses 1 through 4), and after the 4th dose, 1000mg is given for the next 6 weeks depending on the cycle. All doses of Dostarlimab may cost you a total of 77 lakhs (approx.). For a person whose annual income is around 1-2 lakhs, it is impossible for them to afford such an expensive treatment. Previous studies have shown that the annual death rate from all cancer types, in 2007-2011, was 12% higher in rural areas with persistent poverty than the urban counties in the US. Approximately US$1.16 trillion is reckoned as the total economic cost of cancer. Even if someone covers up the treatment cost through loans, they may experience material and psychologic stress due to this burden.

Trials

In April 2017, during the early phase of Dostarlimab production, trials were done on 290 patients who were being miserable due to advanced or recurrent DNA mismatch repair deficient/ microsatellite instability-high (dMMR/ MSI-H) or mismatch repair proficient/ microsatellite stability (MMRp/ MSS) endometrial cancer. According to the types these patients were split up into two batches with identical characteristics – A1 & A2 for the further follow-up. In the combined cohorts, fatigue (17.6%), diarrhea (13.8%), and nausea (13.8%) of grade 1 & 2 were the most common treatment-related adverse events (TRAEs) with occurrence of grade 3 TRAEs in 16.6% of the patients. Due to the fear of TRAEs and some unbearable side effects, 5.5% of the patients discontinued dostarlimab but among the patients who completed the treatment, no deaths were explicable to dostarlimab.

Another trial, where a total of 125 patients were examined covering 41 MSI-H (33%) and 79 MSS (63%) patients in addition with 5 more suffering from an unknown MSI status (4%). The result was not much different from the previous one; as final data showed that 88 out of the 125 patients (70.4%) had atleast one treatment-emergent adverse event having fatigue (14.4%), diarrhea (12.8%), and nausea (12%) as the frequent symptoms. Rest of them were either all well or having some minor problems. There were almost 20 trials performed to observe the working of dostarlimab, including a handful for breast cancer as well and that volume is not shocking according to Padmanee Sharma, MD, PhD, professor genitourinary medical oncology and immunology, and scientific director of the James P. Allison Institute at MD Anderson Cancer Center.

The final trial which gave dostarlimab the approval from the FDA in 2021, was performed on 12 patients with mismatch-repair deficient stage II or III rectal adenocarcinoma. A total of 18 patients were selected, from which only 12 went through the treatment, in which they were asked to take a drug every 3 weeks for 6 months. In every case, the rectal cancer disappeared completely without the need of any kind of standard therapy or surgery after the 6 months to further 25 months, thus showing 100% recovery but the patients who took part in the trial had a specific of rectal cancer. This can be taken in both positive and negative ways but if we find a way to make this immunotherapy drug more effective on other cancer types, then it can finally be called as a 'cancer miracle cure'. Dostarlimab has showed a promise in such a small clinical trial and it is now used in a class of medications to treat some other cancers such as combination of niraparib (Zejula) and dostarlimab-gxly (Jemperli) for platinum-resistant ovarian cancer though it did not reach the conception for second-stage growth; and the combination of cobolimab and dostarlimab for advanced metastatic melanoma.

3. Conclusion

Dostarlimab is now considered as the 'master start' in the world of cancer's cure but due to the fear of the occurrence of such adverse effects, will patients of all age groups go through this treatment? Several trials are going on using dostarlimab to improve and enhance its effects and make it capable of curing all types of cancer. For now, it is particularly treating dMMR/ MSI-H in endometrial cancer but has been useful in treating colorectal cancers as well. Colorectal cancers are the third most leading causes of human health problems globally in both men and women. Australia or New Zealand is estimated to have the highest number of colorectal cancer cases and lowest cases in Western Africa. According to the National Cancer Institute (NCI), there will be 151,030 new cases of colorectal cancer and 52,580 deaths in 2022 in the US, due to colorectal cancer. The method used to create Dostarlimab is becoming a key technique to create combination of drugs for cancer treatment. They may be helpful in treating cancer but age and financial issues will still be the matter of conscience. Doctors and scientists from around the world are trying their best to overcome the after effects of this and make it more useful in the medicaments of different cancers.

References

[1] Sharpe A, Pauken K. The diverse functions of the PD1 inhibitory pathway. *Nat Rev Immunol* 18, 153-167(2018). https://doi.org/10.1038/nri.2017.108
[2] "Dostarlimab". Drug Information Portal. *U.S. National Library of Medicine* (free encyclopedia)
[3] Nikolas Patsaukis, Qi Wang, Laura Strauss, Vassiliki A. Boussiotis. *Science Advances* 38, (2020). https://doi.org/10.1126/sciadv.abd2712
[4] Oaknin A, Gilbert L, Tinker A, et al. 272 Dostarlimab in Advanced/ Recurrent Mismatch Repair Deficient/ Microsatellite Instability High or Proficient/ Stable Endometrial Cancer: the GARNET Study. *International Journal of Gynecologic Cancer* 2021; 31: A85-A86. https://ijgc.bmj.com/content/ijgc/31/Suppl_3/A85.full.pdf
[5] Kasherman L, Ahrari S, Lheureux S. Dostarlimab in the Treatment of Recurrent or Primary Advanced Endometrial Cancer. *Future Oncol.* 2021 Mar; 17(8):877-892. https://doi.org/10.2217/fon-2020-0655.Epub2020Nov30.PMID:33251877
[6] Times of India (Newspaper)
[7] "European Commission Approves Jemperli (dostarlimab), The First Anti-PD-1 Therapy Approved for Recurrent or Advanced dMMR/ MSI-H Endometrial Cancer in Europe". (Press Release). *AnaptyBio Inc.* 23 April 2021.
[8] "FDA grants accelerated approval to dostarlimab-gxly for dMMR endometrial cancer". *U.S. Food and Drug Administration (FDA)* (Press Release). 22 April 2021.
[9] "FDA grants accelerated approval to dostarlimab-gxlydMMR advanced solid tumors". *U.S. Food and Drug Administration (FDA)* (Press Release).18 August 2021.
[10] "Data from GARNET study indicates robust activity of dostarlimab in patients with advanced or recurrent endometrial cancer". *GSK* (Press Release)
[11] Prabhat Prakash, Prathiba Raju. Indian Oncologists take on Dostarlimab- new breakthrough in cancer treatment? *ETHealth World*. 2022 June. https://health.economictimes.indiatimes.com/amp/news/industry/dostarlimab-possible-breakthrough-in-cancer-treatment/92082610
[12] Neha Pathak. Understanding Endometrial Cancer- the Basics. *WebMD|Cancer Center*. 2022 May. https://webmd.com/cancer/understanding-endometrial-cancer-basics
[13] ShiekhahAlzahrani, Huda Al Doghaither, Ayat Al-Ghafari. General insight into cancer: An overview of Colorectal cancer (Review). *Molecular and Clinical Oncology*. 2021 Nov. https://doi.org/10.3892/mco.2021.2433
[14] Fazeli MS, Keramati MR. Rectal Cancer: a review. *MedJ Islam Repub Iran*. 2015; 29: 171. https://ncbi.nlm.nih.gov/pmc/articles/PMC4431429/
[15] GLOBOCAN2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012: International Agency for research on Cancer. *World Health Organization*; 2014. https://globocan.iarc.fr/Pages/fact_sheets_cancer:aspx
[16] Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer Statistics. *CA Cancer JClin*. 2022; 72(1): 7-33. https://doi.org/10.3322/caac.21708
[17] Cancer Facts and Figures 2022 American Cancer Society, 2022. https://cancer.org/research/cancer-facts-statistics/all-cancer-facts-figures-2022.html.
[18] Andres Redondo, Alejandro Gallego, Marta Mendiola. Dostarlimab for the treatment of advanced endometrial cancer. *Expert Review of Clinical Pharmacology*, 15:1, 1-9. https://doi.org/10.1080/17512433.2022.2044791
[19] Markham A. Dostarlimab: First Approval. *Drugs*. 2021; 81(10): 1213-1219. https://doi.org/10.1007/s40265-021-01539-5
[20] Anne-Claire HB, Kathleen NM, B Asselain, et al. ENGOT-0V44/ FIRST study: A randomized, double-blind, adaptive, phase III study of platinum-based therapy with dostarlimab (TSR-042) + niraparib versus standard-of-care (SOC) platinum-based therapy as first line treatment of stage ¾ non-mucinous epithelial ovarian cancer (OC). *Journal of Clinical Oncology*. 2019, 37:15_suppl, TPS5600-TPS5600. https://doi.org/10.1200/JCO.2019.37.15_suppl.TPS5600
[21] Jessica Norris. Colorectal Cancer: All the people in this small trial emerged cancer-free. *Medical News Today*. 2022 June. https://medicalnewstoday.com/articles/colorectal-cancer-all-the-people-in-this-small-trial-emerged-cancer-free
[22] NCI Staff. Persistent Poverty linked to Increased Risk of Dying from Cancer. National Cancer Institute. 2020 Nov. https://cancer.gov/news-events/cancer-currents-blog/2020/persistent-poverty-increased-cancer-death-risk
[23] Global and National Impact. World Cancer Day. 2022 Feb. https://www.worldcancerday.org/financial-and-economic-impact
[24] Korin Miller. What Else can Dostarlimab Treat? *Verywell Health*. 2022 June. https://verywellhealth.com/what-else-can-dostarlimab-treat-5496751